Back to top
more

AstraZeneca (AZN)

(Delayed Data from NSDQ)

$77.07 USD

77.07
4,552,668

-0.62 (-0.80%)

Updated Sep 18, 2025 04:00 PM ET

After-Market: $77.27 +0.20 (0.26%) 5:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

4 Drug Stocks Worth a Look on Promising Cancer Pipeline

by Zacks Equity Research

Cancer is the second most common cause of death in the U.S. preceded only by heart disease. We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.

    Zacks Equity Research

    Valeant (VRX) Continues to Lose Ground: Can It Bounce Back?

    by Zacks Equity Research

    Valeant has been caught up in various controversies due to price hike of specialty drugs, erroneous financial reporting and termination of contracts with Philidor Rx Services and woes do not end.

      Zacks Equity Research

      Parkinson's Now a Hot Therapeutic Area: What's Up Lately?

      by Zacks Equity Research

      Parkinson's disease is a lucrative area due to lack of curative therapy in this space. Many players are trying to bring new treatments to the market. A lot has happened in last couple of months.

        Arpita Dutt headshot

        Pharma Stock Roundup: Novartis CAR-T Drug Gets FDA Nod, Lilly Gives Baricitinib Update

        by Arpita Dutt

        It was a landmark week for the pharmaceutical sector and the medical community with the FDA approving Novartis' (NVS) Kymriah, the first CAR-T cell treatment to be approved in the United States.

          Zacks Equity Research

          AstraZeneca and Takeda Ink Deal to Develop Parkinson's Drug

          by Zacks Equity Research

          AstraZeneca (AZN) and Takeda Pharmaceutical Company entered into an agreement to jointly develop and commercialize MEDI1341 for the potential treatment of Parkinson's disease.

            Zacks Equity Research

            Novo Nordisk's Victoza Gets FDA Nod for Label Expansion

            by Zacks Equity Research

            Novo Nordisk's (NVO) Victoza receives FDA nod for its label expansion to include cardiovascular events in adult patients with type II diabetes. Shares up.

              Zacks Equity Research

              AstraZeneca's Faslodex Gets FDA Nod in First-Line Setting

              by Zacks Equity Research

              AstraZeneca (AZN) drug Faslodex receives FDA approval for a label extension for Faslodex in the first-line monotherapy setting for the treatment of advanced breast cancer.

                Arpita Dutt headshot

                Pharma Stock Roundup: Roche Drug Gets Priority Review, EU Nod for Novartis Drug

                by Arpita Dutt

                It was a pretty slow week with key highlights including regulatory updates from companies like Roche (RHHBY) and Novartis.

                  Zacks Equity Research

                  Pfizer's Ibrance in First-Line Combo Breast Cancer Study

                  by Zacks Equity Research

                  Pfizer, Inc. (PFE) and six international cancer research groups are collaborating on a combination study to explore the use of Ibrance for first-line treatment of advanced breast cancer.

                    Zacks Equity Research

                    Perrigo's (PRGO) OTC Version of Nexium Secures FDA Approval

                    by Zacks Equity Research

                    Perrigo (PRGO) gains an FDA consent for the OTC version of AstraZeneca's Nexium post the ongoing patent lawsuit settlement through an agreement.

                      Zacks Equity Research

                      Ironwood Pharma's Combination Gout Drug Gets FDA Approval

                      by Zacks Equity Research

                      Ironwood Pharmaceuticals, Inc. (IRWD) announced that the FDA has approved Duzallo for the treatment of hyperuricemia in patients with uncontrolled gout.

                        Zacks Equity Research

                        AstraZeneca/Merck's Lynparza Gets FDA Nod for Label Expansion

                        by Zacks Equity Research

                        AstraZeneca, plc (AZN) and partner Merck's ovarian cancer drug, Lynparza has received FDA approval for new tablet formulation and a broader U.S. label.

                          Arpita Dutt headshot

                          Pharma Stock Roundup: Multiple Sclerosis Drug Prices in Focus, Mixed Data on BMY's Opdivo

                          by Arpita Dutt

                          Key highlights this week in the pharmaceutical sector include the launch of a drug pricing probe, a resignation from the President's manufacturing council and data on Bristol-Myers' (BMY) Opdivo.

                            Zacks Equity Research

                            Can Pfizer Bank on New Immunotherapy Bavencio for Growth?

                            by Zacks Equity Research

                            Pfizer, Inc.'s (PFE) newly approved anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant top-line driver for this New York-based pharma giant.

                              Zacks Equity Research

                              Bristol-Myers Opdivo Fails Kidney Cancer Trial CheckMate-214

                              by Zacks Equity Research

                              Bristol-Myers Squibb Company (BMY) announced disappointing top-line results from the CheckMate-214 trial on Opdivo in renal cell carcinoma.

                                Zacks Equity Research

                                Will Nektar's (NKTR) Candidates Enhance Growth in 2017?

                                by Zacks Equity Research

                                Nektar Therapeutics (NKTR) develops several candidates across important therapeutic areas ranging from oncology, pain, anti-infectives to immunology.

                                  Zacks Equity Research

                                  Impax Laboratories (IPXL) Q2 Earnings Beat, Revenues Up Y/Y

                                  by Zacks Equity Research

                                  Impax Laboratories (IPXL) reported positive second-quarter results with earnings and sales both beating estimates. The company has strengthened its generic portfolio with additional approvals during the quarter.

                                    Zacks Equity Research

                                    Valeant (VRX) Beats Q2 Earnings, Sales in Line, Trims View

                                    by Zacks Equity Research

                                    Valeant's (VRX) second-quarter results were encouraging but the company trimmed its guidance due to recent divestitures.

                                      Zacks Equity Research

                                      Inovio (INO) Q2 Loss Narrower Than Expected, Revenues Beat

                                      by Zacks Equity Research

                                      Inovio Pharmaceuticals (INO) reports narrower-than-expected loss with revenue beating estimates. Moreover, the top line significantly increases year over year.

                                        Zacks Equity Research

                                        Ironwood (IRWD) Q2 Loss Widens, Revenues Miss, Stock Up

                                        by Zacks Equity Research

                                        Ironwood Pharmaceuticals' (IRWD) second-quarter results were dismal, missing sales and earnings estimates.

                                          Arpita Dutt headshot

                                          Pharma Stock Roundup: Mixed 2Q Results from Pfizer, Bristol-Myers Announces IO Deals

                                          by Arpita Dutt

                                          Pfizer's (PFE) results were mixed while Teva had a dismal quarter with the company missing estimates as well as cutting its outlook and guidance.

                                            Zacks Equity Research

                                            The Zacks Analyst Blog Highlights: Merck, Citigroup, AstraZeneca, HSBC and Sprint

                                            by Zacks Equity Research

                                            The Zacks Analyst Blog Highlights: Merck, Citigroup, AstraZeneca, HSBC and Sprint

                                              Arpita Dutt headshot

                                              Pharma Stock Roundup: Q2 Earnings Results from Merck, Lilly, Bristol-Myers & More

                                              by Arpita Dutt

                                              Companies like AstraZeneca (AZN) and Lilly saw their shares fall after the release of second quarter results.

                                                Zacks Equity Research

                                                AstraZeneca (AZN) Beats on Q2 Earnings, Falls on Failed Study

                                                by Zacks Equity Research

                                                AstraZeneca PLC (AZN) reported second-quarter 2017 core earnings of 87 cents per ADS, which beat the Zacks Consensus Estimate of 41 cents. Failure in lung cancer study on Imfinzi however pulled the stock down.

                                                  Zacks Equity Research

                                                  Merck (MRK) Beats on Q2 Earnings and Sales, Keeps 2017 View

                                                  by Zacks Equity Research

                                                  Merck & Co., Inc. (MRK) beat estimates for both earnings and sales in Q2 mainly backed by strong sales of PD-1 inhibitor, Keytruda.